Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$7.01
-3.0%
$6.32
$3.93
$7.54
$370.74M1.55730,185 shs544,505 shs
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$6.60
-7.0%
$8.46
$3.98
$23.40
$324.59M0.591.73 million shs1.96 million shs
CervoMed Inc. stock logo
CRVO
CervoMed
$9.43
+3.3%
$7.96
$1.80
$20.63
$84.48M-0.79804,349 shs75,224 shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$6.41
-6.8%
$7.10
$2.32
$9.90
$372.15M2.47979,802 shs277,606 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.00%+1.40%+10.72%+12.62%+31.10%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
0.00%-10.80%+0.57%-30.73%+55.70%
CervoMed Inc. stock logo
CRVO
CervoMed
0.00%-9.78%+1.67%+7.79%-44.06%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
0.00%+0.88%-11.91%+6.83%-24.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
4.4117 of 5 stars
3.52.00.04.52.52.51.3
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
3.0571 of 5 stars
4.62.00.00.02.20.80.6
CervoMed Inc. stock logo
CRVO
CervoMed
2.3154 of 5 stars
3.42.00.00.02.31.70.6
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
0.9195 of 5 stars
2.31.00.00.02.21.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
3.00
Buy$19.50178.17% Upside
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
3.11
Buy$22.56241.75% Upside
CervoMed Inc. stock logo
CRVO
CervoMed
2.78
Moderate Buy$23.71151.48% Upside
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.63
Moderate Buy$7.5718.12% Upside

Current Analyst Ratings Breakdown

Latest CRVO, FULC, ABEO, and CAPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
8/18/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $31.00
8/15/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$19.00 ➝ $20.00
8/12/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $16.00
8/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $15.00
8/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
7/30/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $5.00
7/29/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $27.00
7/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$4.00 ➝ $12.00
7/25/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
7/14/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$400K898.66N/AN/A$1.01 per share6.94
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$13.39M22.53N/AN/A$3.20 per share2.06
CervoMed Inc. stock logo
CRVO
CervoMed
$9.74M8.96N/AN/A$4.50 per share2.10
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M4.33N/AN/A$4.51 per share1.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$63.73M$0.7010.01N/AN/AN/A89.05%45.64%11/13/2025 (Estimated)
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$40.47M-$1.64N/AN/AN/A-181.71%-62.71%-50.82%11/12/2025 (Estimated)
CervoMed Inc. stock logo
CRVO
CervoMed
-$16.29M-$2.61N/AN/AN/A-290.72%-59.15%-53.64%11/11/2025 (Estimated)
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)

Latest CRVO, FULC, ABEO, and CAPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million
8/11/2025Q2 2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$0.48-$0.57-$0.09-$0.57$2.60 millionN/A
8/8/2025Q2 2025
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.57-$0.70-$0.13-$0.70$1.45 million$1.76 million
7/29/2025Q2 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/AN/AN/AN/AN/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.09
6.73
6.65
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/A
4.37
4.37
CervoMed Inc. stock logo
CRVO
CervoMed
N/A
8.20
8.20
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
24.42
24.42

Institutional Ownership

CompanyInstitutional Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
80.56%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
21.68%
CervoMed Inc. stock logo
CRVO
CervoMed
25.15%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%

Insider Ownership

CompanyInsider Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
6.90%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
10.50%
CervoMed Inc. stock logo
CRVO
CervoMed
35.40%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
9051.28 million48.51 millionOptionable
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
10145.72 million40.92 millionOptionable
CervoMed Inc. stock logo
CRVO
CervoMed
49.25 million5.98 millionNot Optionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10054.09 million50.31 millionOptionable

Recent News About These Companies

FULC Fulcrum Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abeona Therapeutics stock logo

Abeona Therapeutics NASDAQ:ABEO

$7.01 -0.22 (-3.04%)
Closing price 04:00 PM Eastern
Extended Trading
$7.08 +0.07 (+1.06%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Capricor Therapeutics stock logo

Capricor Therapeutics NASDAQ:CAPR

$6.60 -0.50 (-7.04%)
Closing price 04:00 PM Eastern
Extended Trading
$6.61 +0.01 (+0.15%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

CervoMed stock logo

CervoMed NASDAQ:CRVO

$9.43 +0.30 (+3.29%)
Closing price 04:00 PM Eastern
Extended Trading
$9.40 -0.03 (-0.32%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$6.41 -0.47 (-6.83%)
Closing price 04:00 PM Eastern
Extended Trading
$6.38 -0.03 (-0.39%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.